Join the Spasticity group to help and get support from people like you.
Spasticity News (Page 2)
Parents' Smoking Could Raise Risk for MS in Kids
WEDNESDAY, Dec. 11, 2024 – For children genetically predisposed to develop multiple sclerosis (MS), exposure to cigarette smoke in the family home could raise that risk even higher, new research...
Social Determinants of Health Linked to Brain MRI Outcomes in Pediatric MS
MONDAY, Dec. 2, 2024 – For patients with pediatric-onset multiple sclerosis (POMS), social determinants of health (SDOH) are associated with worse brain magnetic resonance imaging (MRI) outcomes,...
Generic Medications Can Keep OOP Costs Down for Neurological Conditions
WEDNESDAY, Oct. 30, 2024 – Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according...
Cancer Incidence Increased for People With Multiple Sclerosis
WEDNESDAY, Oct. 9, 2024 – Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex, according to a study...
European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20
The annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis was held from Sept. 18 to 20 in Copenhagen, Denmark, and drew more than 8,500 delegates from around the ...
Aggressive, Early Disease-Modifying Therapy May Slow MS Progression
FRIDAY, Sept. 27, 2024 – Reducing or preventing paramagnetic rim lesions (PRLs) could significantly slow multiple sclerosis (MS) progression, according to a study presented at the annual meeting of...
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...
FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS
THURSDAY, Sept. 26, 2024 – The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection...
Guidelines Provided for Diagnosis of Pediatric, Late-Onset Multiple Sclerosis
TUESDAY, Sept. 24, 2024 – In a clinical review conducted by an international committee of multiple sclerosis (MS) experts in pediatric and adult MS and published online Sept. 16 in JAMA Neurology,...
FDA Approves Fleqsuvy (baclofen oral suspension) for the Treatment of Spasticity
WOBURN, MA, February 7, 2022 – Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of patients with u...
FDA Approves Lyvispah (baclofen) Oral Granules for the Treatment of Spasticity
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 7, 2021 /PRNewswire/ – Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saol's Lyvispah (baclofen)...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of Botox® ...
Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children
CAMBRIDGE, Mass.--(BUSINESS WIRE) July 09, 2020 --Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License...
Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
June 16, 2017 – Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport (abobotulinumtoxinA) for injection...